Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SURPRISE: Tocilizumab in RA Patients
NCT01120366Phase 4Completed
- Sponsor
- SURPRISE Study Group
- Start
- Oct 2009
- Primary completion
- Dec 2014
- Modality
- Antibody Conjugates, Recombinant Proteins and Enzymes, Engineered Antibody Formats
- Countries
- 1
01
Overview
A Phase 4 trial of tocilizumab in rheumatoid arthritis (RA), sponsored by SURPRISE Study Group. Started Oct 2009; status: completed.
02
Drugs
tocilizumab
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT01120366.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01120366.